Core Viewpoint - Bank of America Securities reports that Giant Bio (02367) slightly exceeded expectations in the first half of the year, with total revenue of 3.113 billion RMB, representing a year-on-year growth of 22.5% [1] Group 1: Financial Performance - The company’s revenue forecast for its brand Comfy has been raised based on strong performance in the first half and robust online sales in July [1] - Total revenue forecasts for 2025 to 2027 have been increased by 1.9% each [1] - Due to a decrease in live streaming revenue contribution, the sales expense ratio for 2025 has been lowered [1] Group 2: Earnings Forecast - Earnings per share forecasts for 2025 to 2027 have been adjusted upwards by 2%, 1.7%, and 1.7% respectively [1] - The target price for the company has been slightly increased from 79 HKD to 79.5 HKD [1] - The "Buy" rating is reaffirmed, as there is high visibility for growth in the restructured collagen product line [1]
美银证券：微升巨子生物目标价至79.5港元 重申“买入”评级